瘤学篮子试验的风险和益处:系统审查和元分析
Katarzyna Klas1,2, Karolina Strzebonska1, Lucja Zaborowska1,2,3
1Research Ethics in Medicine Study Group (REMEDY), Department of Bioethics, Faculty of Health Sciences, Jagiellonian University Medical College, Michalowskiego 12, 31-126, Kraków, Poland.
Targeted oncology
|October 25, 2024
概括
在瘤学的篮子临床试验显示了18%的客观反应率. 虽然风险包括30.4%的3/4级毒性,但这些试验对于精准医学的进步至关重要.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 精准医学是一门精准的医学.
背景情况:
- 精准医学正在通过新的临床试验设计改变瘤学研究.
- 篮子临床试验评估基于分子特征的多种瘤类型的治疗方法.
- 这些试验旨在确定可能从特定实验疗法中受益的患者.
研究的目的:
- 系统地评估与瘤学的篮子临床试验相关的风险和益处.
- 提供与治疗相关的不良事件和疗效结果的基于证据的理解.
主要方法:
- 在PubMed,Embase和ClinicalTrials.gov.gov网站上进行了系统的文献搜索.
- 分析了2001年至2023年间发表的篮子临床试验数据.
- 关键指标包括客观反应率,无进展生存率,整体生存率和与治疗相关的不良事件 (3-5级).
主要成果:
- 这项研究分析了75个涉及7659名患者的篮子试验.
- 综合的客观反应率为18.0%,与治疗相关的死亡率为0.7%.
- 3/4级药物相关毒性影响了30.4%的患者;中位数无进展生存时间为3.1个月,总生存时间为8.9个月.
结论:
- 篮子临床试验为瘤学中的精准医学提供了有价值的框架.
- 结果为这些新型试验设计中的风险-益处沟通提供了经验基础.
- 结果可以为未来针对性治疗的临床试验模型的改进提供信息.
更多相关视频
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


